 David Badesch
Concepts (502)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 106 | 2023 | 1736 | 6.840 |
Why?
| | Antihypertensive Agents | 31 | 2019 | 430 | 3.080 |
Why?
| | Epoprostenol | 23 | 2015 | 133 | 1.990 |
Why?
| | Vasodilator Agents | 12 | 2015 | 307 | 1.230 |
Why?
| | Registries | 20 | 2022 | 1763 | 1.140 |
Why?
| | Familial Primary Pulmonary Hypertension | 16 | 2023 | 190 | 1.010 |
Why?
| | Piperazines | 8 | 2014 | 313 | 0.990 |
Why?
| | Sulfones | 7 | 2012 | 97 | 0.970 |
Why?
| | Pulmonary Wedge Pressure | 8 | 2020 | 63 | 0.960 |
Why?
| | Exercise Tolerance | 19 | 2023 | 213 | 0.890 |
Why?
| | Hemodynamics | 28 | 2023 | 1017 | 0.890 |
Why?
| | Vascular Resistance | 9 | 2023 | 337 | 0.870 |
Why?
| | Scleroderma, Systemic | 6 | 2021 | 96 | 0.810 |
Why?
| | Practice Guidelines as Topic | 7 | 2020 | 1398 | 0.800 |
Why?
| | Connective Tissue Diseases | 5 | 2018 | 71 | 0.790 |
Why?
| | Sulfonamides | 12 | 2018 | 445 | 0.750 |
Why?
| | Exercise Test | 11 | 2020 | 545 | 0.720 |
Why?
| | Phenylpropionates | 5 | 2011 | 16 | 0.690 |
Why?
| | Respiratory System Agents | 2 | 2023 | 22 | 0.680 |
Why?
| | Pulmonary Artery | 14 | 2023 | 1028 | 0.660 |
Why?
| | Natriuretic Peptide, Brain | 9 | 2021 | 96 | 0.630 |
Why?
| | Pyridazines | 5 | 2011 | 45 | 0.630 |
Why?
| | Double-Blind Method | 21 | 2023 | 1664 | 0.590 |
Why?
| | Adult | 70 | 2023 | 30654 | 0.580 |
Why?
| | Humans | 135 | 2023 | 115038 | 0.570 |
Why?
| | Endothelin Receptor Antagonists | 9 | 2015 | 58 | 0.550 |
Why?
| | Middle Aged | 71 | 2022 | 26826 | 0.520 |
Why?
| | Disease Management | 6 | 2016 | 563 | 0.470 |
Why?
| | Lung Transplantation | 9 | 2002 | 246 | 0.450 |
Why?
| | Anticoagulants | 3 | 2016 | 546 | 0.430 |
Why?
| | Thrombosis | 1 | 2016 | 301 | 0.420 |
Why?
| | Male | 83 | 2022 | 55729 | 0.420 |
Why?
| | Cardiac Catheterization | 12 | 2023 | 535 | 0.420 |
Why?
| | Anemia, Sickle Cell | 5 | 2014 | 217 | 0.420 |
Why?
| | Female | 80 | 2022 | 59610 | 0.410 |
Why?
| | Risk Assessment | 13 | 2021 | 2976 | 0.400 |
Why?
| | Consensus | 1 | 2014 | 534 | 0.400 |
Why?
| | Prognosis | 16 | 2021 | 3334 | 0.400 |
Why?
| | Treatment Outcome | 26 | 2023 | 9122 | 0.380 |
Why?
| | Recombinant Fusion Proteins | 3 | 2023 | 616 | 0.380 |
Why?
| | Aged | 37 | 2021 | 19119 | 0.370 |
Why?
| | Survival Rate | 15 | 2022 | 1646 | 0.370 |
Why?
| | Thinness | 1 | 2011 | 87 | 0.360 |
Why?
| | Prostaglandins | 3 | 2007 | 78 | 0.360 |
Why?
| | Blood Pressure | 8 | 2014 | 1539 | 0.350 |
Why?
| | Activities of Daily Living | 3 | 2016 | 351 | 0.330 |
Why?
| | Oxygen Consumption | 1 | 2012 | 588 | 0.330 |
Why?
| | Pyrimidines | 3 | 2018 | 375 | 0.320 |
Why?
| | Hypertension, Portal | 4 | 2011 | 62 | 0.320 |
Why?
| | Sildenafil Citrate | 8 | 2014 | 57 | 0.310 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2201 | 0.310 |
Why?
| | Coagulants | 1 | 2008 | 12 | 0.310 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4631 | 0.310 |
Why?
| | Factor VIIa | 1 | 2008 | 36 | 0.310 |
Why?
| | Purines | 8 | 2014 | 159 | 0.290 |
Why?
| | Depressive Disorder | 1 | 2010 | 333 | 0.290 |
Why?
| | Mixed Connective Tissue Disease | 2 | 2010 | 8 | 0.280 |
Why?
| | Prospective Studies | 16 | 2021 | 6232 | 0.280 |
Why?
| | Evidence-Based Medicine | 4 | 2019 | 676 | 0.270 |
Why?
| | Health Status | 2 | 2016 | 722 | 0.270 |
Why?
| | Quality of Life | 10 | 2021 | 2359 | 0.260 |
Why?
| | Hemorrhage | 2 | 2008 | 618 | 0.260 |
Why?
| | Pulmonary Medicine | 3 | 2019 | 87 | 0.250 |
Why?
| | Phosphodiesterase 5 Inhibitors | 3 | 2014 | 36 | 0.250 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2012 | 928 | 0.240 |
Why?
| | Dose-Response Relationship, Drug | 11 | 2021 | 1857 | 0.230 |
Why?
| | Follow-Up Studies | 15 | 2018 | 4420 | 0.230 |
Why?
| | Hospitalization | 6 | 2022 | 1754 | 0.230 |
Why?
| | Adolescent | 22 | 2021 | 17862 | 0.230 |
Why?
| | Castleman Disease | 1 | 2003 | 13 | 0.220 |
Why?
| | Body Mass Index | 1 | 2011 | 1967 | 0.220 |
Why?
| | United States | 20 | 2022 | 12224 | 0.220 |
Why?
| | Herpesvirus 8, Human | 1 | 2003 | 62 | 0.220 |
Why?
| | DEAE-Dextran | 1 | 2023 | 1 | 0.220 |
Why?
| | Biomarkers | 6 | 2021 | 3419 | 0.210 |
Why?
| | Muscle, Smooth, Vascular | 6 | 1994 | 417 | 0.210 |
Why?
| | Ventricular Function, Right | 5 | 2009 | 252 | 0.210 |
Why?
| | Phosphodiesterase Inhibitors | 4 | 2009 | 82 | 0.200 |
Why?
| | Herpesviridae Infections | 1 | 2003 | 138 | 0.200 |
Why?
| | Pyrazoles | 2 | 2015 | 362 | 0.200 |
Why?
| | Lung | 7 | 2019 | 3595 | 0.200 |
Why?
| | Insulin-Like Growth Factor I | 4 | 1994 | 286 | 0.190 |
Why?
| | Fluid Shifts | 1 | 2020 | 1 | 0.180 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2021 | 61 | 0.180 |
Why?
| | Walking | 8 | 2014 | 424 | 0.180 |
Why?
| | Drug Therapy, Combination | 6 | 2014 | 955 | 0.180 |
Why?
| | Methamphetamine | 1 | 2021 | 51 | 0.180 |
Why?
| | Rituximab | 1 | 2021 | 150 | 0.180 |
Why?
| | Echocardiography | 4 | 2020 | 557 | 0.180 |
Why?
| | Infusions, Intravenous | 7 | 2009 | 372 | 0.180 |
Why?
| | Disease Progression | 5 | 2015 | 2389 | 0.180 |
Why?
| | Heart | 2 | 2023 | 610 | 0.180 |
Why?
| | Vasculitis | 2 | 1998 | 71 | 0.170 |
Why?
| | Somatomedins | 2 | 1990 | 29 | 0.170 |
Why?
| | Sodium Chloride | 1 | 2020 | 136 | 0.170 |
Why?
| | Young Adult | 10 | 2021 | 10498 | 0.170 |
Why?
| | Thorax | 1 | 2019 | 41 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2021 | 221 | 0.160 |
Why?
| | Diagnostic Techniques, Respiratory System | 1 | 2019 | 5 | 0.160 |
Why?
| | Endothelin A Receptor Antagonists | 2 | 2011 | 24 | 0.160 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.160 |
Why?
| | SOXF Transcription Factors | 1 | 2018 | 18 | 0.160 |
Why?
| | Isoxazoles | 3 | 2008 | 52 | 0.160 |
Why?
| | Time Factors | 14 | 2018 | 6141 | 0.160 |
Why?
| | Algorithms | 5 | 2019 | 1488 | 0.160 |
Why?
| | Obesity | 1 | 2011 | 2524 | 0.160 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 76 | 0.160 |
Why?
| | Thiophenes | 3 | 2008 | 108 | 0.160 |
Why?
| | Administration, Oral | 9 | 2015 | 730 | 0.160 |
Why?
| | Transforming Growth Factor beta | 1 | 2021 | 448 | 0.160 |
Why?
| | Peptide Fragments | 4 | 2021 | 668 | 0.150 |
Why?
| | Liver Diseases | 3 | 2011 | 259 | 0.150 |
Why?
| | Severity of Illness Index | 9 | 2014 | 2551 | 0.150 |
Why?
| | Blood Coagulation | 2 | 2016 | 221 | 0.150 |
Why?
| | Drug Monitoring | 1 | 2019 | 184 | 0.150 |
Why?
| | Psychometrics | 2 | 2018 | 608 | 0.150 |
Why?
| | Proportional Hazards Models | 6 | 2022 | 1080 | 0.140 |
Why?
| | Comorbidity | 5 | 2019 | 1457 | 0.140 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2018 | 129 | 0.140 |
Why?
| | Pyridines | 2 | 2015 | 425 | 0.140 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 290 | 0.130 |
Why?
| | B-Lymphocytes | 1 | 2021 | 772 | 0.130 |
Why?
| | Cohort Studies | 7 | 2020 | 4904 | 0.130 |
Why?
| | Iloprost | 2 | 2006 | 46 | 0.120 |
Why?
| | Hemolysis | 2 | 2014 | 146 | 0.120 |
Why?
| | Tetrazoles | 1 | 2015 | 32 | 0.120 |
Why?
| | Pulmonary Edema | 1 | 1995 | 116 | 0.120 |
Why?
| | Graft Rejection | 1 | 1998 | 522 | 0.120 |
Why?
| | Pilot Projects | 4 | 2010 | 1375 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 722 | 0.120 |
Why?
| | Survival Analysis | 8 | 2018 | 1211 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2018 | 3015 | 0.120 |
Why?
| | Patient Reported Outcome Measures | 1 | 2016 | 250 | 0.120 |
Why?
| | Delphi Technique | 1 | 2014 | 163 | 0.110 |
Why?
| | Societies, Medical | 2 | 2015 | 678 | 0.110 |
Why?
| | Models, Theoretical | 2 | 2015 | 517 | 0.110 |
Why?
| | Acute Disease | 3 | 2008 | 915 | 0.110 |
Why?
| | Colorado | 3 | 2022 | 4089 | 0.110 |
Why?
| | Antibodies, Antinuclear | 1 | 1993 | 60 | 0.110 |
Why?
| | Echocardiography, Doppler | 2 | 2014 | 92 | 0.110 |
Why?
| | Hypothyroidism | 1 | 1993 | 65 | 0.110 |
Why?
| | Incidence | 5 | 2015 | 2318 | 0.110 |
Why?
| | Respiratory Function Tests | 5 | 2018 | 523 | 0.110 |
Why?
| | Protein Kinase C | 2 | 1994 | 275 | 0.110 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 1995 | 240 | 0.100 |
Why?
| | Endpoint Determination | 2 | 2010 | 69 | 0.100 |
Why?
| | Risk Factors | 9 | 2018 | 8642 | 0.100 |
Why?
| | Walk Test | 2 | 2023 | 52 | 0.100 |
Why?
| | Injections, Subcutaneous | 2 | 2023 | 133 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2009 | 1214 | 0.100 |
Why?
| | Pulmonary Circulation | 3 | 2018 | 407 | 0.100 |
Why?
| | Prevalence | 4 | 2010 | 2255 | 0.100 |
Why?
| | United Kingdom | 3 | 2021 | 227 | 0.100 |
Why?
| | Survival | 1 | 2011 | 37 | 0.100 |
Why?
| | Respiration, Artificial | 1 | 1995 | 526 | 0.100 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1355 | 0.100 |
Why?
| | Peptidyl-Dipeptidase A | 3 | 2003 | 53 | 0.090 |
Why?
| | Pain | 2 | 2011 | 709 | 0.090 |
Why?
| | Long-Term Care | 1 | 2011 | 76 | 0.090 |
Why?
| | Michigan | 1 | 2010 | 96 | 0.090 |
Why?
| | Reference Values | 2 | 2009 | 748 | 0.090 |
Why?
| | Animals, Newborn | 5 | 1994 | 778 | 0.090 |
Why?
| | Guideline Adherence | 2 | 2018 | 492 | 0.090 |
Why?
| | Aged, 80 and over | 8 | 2021 | 6357 | 0.080 |
Why?
| | Endothelin-1 | 2 | 2002 | 167 | 0.080 |
Why?
| | Pulmonary Alveoli | 2 | 2005 | 374 | 0.080 |
Why?
| | Exercise | 2 | 2018 | 1644 | 0.080 |
Why?
| | Aldosterone | 1 | 2009 | 42 | 0.080 |
Why?
| | Dinoprostone | 1 | 1989 | 185 | 0.080 |
Why?
| | Elastin | 1 | 1989 | 78 | 0.080 |
Why?
| | Vasopressins | 1 | 2009 | 56 | 0.080 |
Why?
| | Pulmonary Eosinophilia | 1 | 1989 | 26 | 0.080 |
Why?
| | Transaminases | 1 | 2008 | 25 | 0.080 |
Why?
| | Vasoconstrictor Agents | 1 | 2009 | 112 | 0.080 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2009 | 72 | 0.080 |
Why?
| | Renal Insufficiency | 1 | 2010 | 136 | 0.080 |
Why?
| | Heart Failure | 2 | 2020 | 1962 | 0.080 |
Why?
| | Retrospective Studies | 7 | 2023 | 12547 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2004 | 399 | 0.080 |
Why?
| | Lung Diseases | 2 | 2010 | 703 | 0.080 |
Why?
| | Genetic Predisposition to Disease | 3 | 2018 | 2108 | 0.080 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2011 | 361 | 0.080 |
Why?
| | Alveolitis, Extrinsic Allergic | 1 | 1989 | 92 | 0.080 |
Why?
| | Hospitals, University | 1 | 2008 | 170 | 0.070 |
Why?
| | Multivariate Analysis | 4 | 2015 | 1435 | 0.070 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2009 | 218 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2018 | 814 | 0.070 |
Why?
| | Autoimmune Diseases | 2 | 2005 | 394 | 0.070 |
Why?
| | Lupus Erythematosus, Systemic | 3 | 2010 | 221 | 0.070 |
Why?
| | Drug Costs | 1 | 2008 | 91 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2009 | 937 | 0.070 |
Why?
| | Educational Measurement | 1 | 1989 | 257 | 0.070 |
Why?
| | Drug Utilization | 1 | 2008 | 167 | 0.070 |
Why?
| | Endothelins | 1 | 2007 | 61 | 0.070 |
Why?
| | Depressive Disorder, Major | 1 | 2010 | 302 | 0.070 |
Why?
| | Airway Obstruction | 1 | 2009 | 168 | 0.070 |
Why?
| | Hypophosphatemia | 1 | 2006 | 18 | 0.070 |
Why?
| | Hypokalemia | 1 | 2006 | 25 | 0.070 |
Why?
| | Calcium Channel Blockers | 1 | 2007 | 115 | 0.070 |
Why?
| | Appetite Depressants | 1 | 2006 | 18 | 0.070 |
Why?
| | Phosphorus | 1 | 2006 | 81 | 0.070 |
Why?
| | Potassium | 1 | 2006 | 128 | 0.070 |
Why?
| | Child | 6 | 2011 | 18407 | 0.070 |
Why?
| | Ventricular Function | 1 | 2006 | 56 | 0.070 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 17 | 0.070 |
Why?
| | Medical Informatics | 1 | 2006 | 91 | 0.060 |
Why?
| | CREST Syndrome | 2 | 2002 | 6 | 0.060 |
Why?
| | Cattle | 5 | 1994 | 924 | 0.060 |
Why?
| | Pleural Diseases | 1 | 2005 | 21 | 0.060 |
Why?
| | Probability | 3 | 2015 | 289 | 0.060 |
Why?
| | Analysis of Variance | 3 | 2009 | 1229 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 3 | 2010 | 1002 | 0.060 |
Why?
| | Predictive Value of Tests | 3 | 2016 | 1812 | 0.060 |
Why?
| | Forecasting | 3 | 2021 | 332 | 0.060 |
Why?
| | Referral and Consultation | 1 | 2010 | 633 | 0.060 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1237 | 0.060 |
Why?
| | Immunohistochemistry | 3 | 2005 | 1634 | 0.060 |
Why?
| | Carbon Monoxide | 2 | 2018 | 65 | 0.060 |
Why?
| | Heart Defects, Congenital | 2 | 2009 | 665 | 0.060 |
Why?
| | Terminology as Topic | 1 | 2005 | 186 | 0.060 |
Why?
| | Age Distribution | 3 | 2010 | 340 | 0.060 |
Why?
| | Sex Distribution | 3 | 2010 | 335 | 0.060 |
Why?
| | Physicians, Family | 1 | 2005 | 201 | 0.060 |
Why?
| | Cardiac Surgical Procedures | 1 | 2008 | 413 | 0.060 |
Why?
| | Hypoxia | 3 | 2018 | 958 | 0.060 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 524 | 0.060 |
Why?
| | Physician's Role | 1 | 2005 | 199 | 0.060 |
Why?
| | Animals | 11 | 2013 | 31867 | 0.050 |
Why?
| | Scleroderma, Localized | 1 | 2002 | 7 | 0.050 |
Why?
| | Statistics, Nonparametric | 2 | 2003 | 387 | 0.050 |
Why?
| | Polymyositis | 1 | 2002 | 15 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2002 | 30 | 0.050 |
Why?
| | Clinical Competence | 1 | 1989 | 899 | 0.050 |
Why?
| | Dermatomyositis | 1 | 2002 | 23 | 0.050 |
Why?
| | Thromboxane-A Synthase | 1 | 2002 | 2 | 0.050 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 752 | 0.050 |
Why?
| | Polymerase Chain Reaction | 2 | 2003 | 999 | 0.050 |
Why?
| | Liver Function Tests | 3 | 2011 | 106 | 0.050 |
Why?
| | Drug Administration Schedule | 4 | 2008 | 719 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2023 | 125 | 0.050 |
Why?
| | Multicenter Studies as Topic | 2 | 2006 | 250 | 0.050 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2021 | 16 | 0.050 |
Why?
| | Biomarkers, Pharmacological | 1 | 2021 | 26 | 0.050 |
Why?
| | Tricuspid Valve Insufficiency | 2 | 2011 | 19 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2018 | 1901 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2002 | 206 | 0.050 |
Why?
| | Least-Squares Analysis | 1 | 2021 | 73 | 0.050 |
Why?
| | Injections, Intravenous | 2 | 2013 | 202 | 0.050 |
Why?
| | Lymph Nodes | 1 | 2003 | 422 | 0.050 |
Why?
| | Tropoelastin | 2 | 1991 | 11 | 0.050 |
Why?
| | Reproductive History | 1 | 2020 | 12 | 0.050 |
Why?
| | Cells, Cultured | 5 | 1994 | 3896 | 0.050 |
Why?
| | Europe | 2 | 2012 | 336 | 0.050 |
Why?
| | Risk | 2 | 2015 | 815 | 0.050 |
Why?
| | Jaw | 1 | 2000 | 15 | 0.040 |
Why?
| | Infusion Pumps | 1 | 2000 | 31 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 2799 | 0.040 |
Why?
| | Cardiac Output | 1 | 2020 | 143 | 0.040 |
Why?
| | Internship and Residency | 1 | 1989 | 941 | 0.040 |
Why?
| | Autoimmunity | 1 | 2005 | 818 | 0.040 |
Why?
| | Lung Diseases, Interstitial | 1 | 2005 | 515 | 0.040 |
Why?
| | Genotype | 4 | 2009 | 1780 | 0.040 |
Why?
| | Delivery of Health Care | 1 | 2006 | 835 | 0.040 |
Why?
| | Radiography | 2 | 1995 | 827 | 0.040 |
Why?
| | Transplantation, Homologous | 2 | 1998 | 390 | 0.040 |
Why?
| | Placebos | 2 | 2011 | 198 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 118 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2021 | 178 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 1999 | 57 | 0.040 |
Why?
| | Gonadal Steroid Hormones | 1 | 2020 | 124 | 0.040 |
Why?
| | Spinal Diseases | 1 | 1999 | 44 | 0.040 |
Why?
| | Immunosuppressive Agents | 3 | 1998 | 651 | 0.040 |
Why?
| | Child, Preschool | 2 | 2011 | 9093 | 0.040 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1999 | 108 | 0.040 |
Why?
| | Uric Acid | 1 | 2000 | 148 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 69 | 0.040 |
Why?
| | Cervical Vertebrae | 1 | 1999 | 106 | 0.040 |
Why?
| | Models, Statistical | 1 | 2022 | 602 | 0.040 |
Why?
| | Methicillin Resistance | 1 | 1998 | 18 | 0.040 |
Why?
| | Plasmapheresis | 1 | 1998 | 22 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2000 | 182 | 0.040 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2018 | 60 | 0.040 |
Why?
| | Cell Division | 4 | 1994 | 758 | 0.040 |
Why?
| | Hemoptysis | 1 | 1998 | 35 | 0.040 |
Why?
| | Capillaries | 1 | 1998 | 91 | 0.040 |
Why?
| | Disease-Free Survival | 2 | 2010 | 617 | 0.040 |
Why?
| | Bronchiolitis Obliterans | 1 | 1998 | 66 | 0.040 |
Why?
| | Mass Screening | 2 | 2018 | 1012 | 0.040 |
Why?
| | Faculty, Medical | 2 | 1990 | 232 | 0.040 |
Why?
| | Biomedical Technology | 1 | 2017 | 40 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1998 | 285 | 0.040 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 1998 | 76 | 0.040 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1997 | 39 | 0.040 |
Why?
| | Health Status Indicators | 2 | 2009 | 154 | 0.030 |
Why?
| | Network Meta-Analysis | 1 | 2016 | 15 | 0.030 |
Why?
| | Colonic Diseases | 1 | 1996 | 25 | 0.030 |
Why?
| | Blood Coagulation Factors | 1 | 1996 | 44 | 0.030 |
Why?
| | Intestinal Perforation | 1 | 1996 | 38 | 0.030 |
Why?
| | Myosin Heavy Chains | 1 | 1997 | 177 | 0.030 |
Why?
| | Mycoplasma | 1 | 1996 | 4 | 0.030 |
Why?
| | Mycoplasma Infections | 1 | 1996 | 13 | 0.030 |
Why?
| | Translating | 1 | 2016 | 36 | 0.030 |
Why?
| | Cardiomyopathy, Dilated | 1 | 1999 | 351 | 0.030 |
Why?
| | Myocardium | 2 | 1998 | 922 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 1997 | 85 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2016 | 130 | 0.030 |
Why?
| | Endothelium, Vascular | 2 | 1994 | 850 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2014 | 2389 | 0.030 |
Why?
| | Desensitization, Immunologic | 1 | 1997 | 117 | 0.030 |
Why?
| | Dyspnea | 2 | 2008 | 218 | 0.030 |
Why?
| | Recurrence | 1 | 1998 | 941 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2016 | 4411 | 0.030 |
Why?
| | Pulmonary Emphysema | 1 | 1998 | 280 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 161 | 0.030 |
Why?
| | Calibration | 1 | 2015 | 126 | 0.030 |
Why?
| | Lactobacillus | 1 | 1994 | 24 | 0.030 |
Why?
| | Fibrinolysis | 1 | 1996 | 160 | 0.030 |
Why?
| | Down Syndrome | 1 | 1999 | 335 | 0.030 |
Why?
| | Immunization, Passive | 1 | 1994 | 73 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 2 | 1994 | 153 | 0.030 |
Why?
| | Drug Approval | 1 | 2015 | 78 | 0.030 |
Why?
| | Focus Groups | 1 | 2016 | 385 | 0.030 |
Why?
| | Antisickling Agents | 1 | 2014 | 5 | 0.030 |
Why?
| | Ferritins | 1 | 2014 | 52 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2014 | 30 | 0.030 |
Why?
| | Immunoglobulins | 1 | 1994 | 143 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 172 | 0.030 |
Why?
| | Staphylococcal Infections | 1 | 1998 | 336 | 0.030 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 1994 | 61 | 0.030 |
Why?
| | Genetic Variation | 1 | 2018 | 876 | 0.030 |
Why?
| | Social Behavior | 1 | 2016 | 267 | 0.030 |
Why?
| | Thyroiditis | 1 | 1993 | 3 | 0.030 |
Why?
| | Raynaud Disease | 1 | 1993 | 5 | 0.030 |
Why?
| | Cytomegalovirus | 1 | 1994 | 145 | 0.030 |
Why?
| | Research | 2 | 2009 | 395 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2014 | 125 | 0.030 |
Why?
| | Pneumonia, Bacterial | 1 | 1994 | 106 | 0.030 |
Why?
| | Immunoenzyme Techniques | 2 | 1994 | 192 | 0.030 |
Why?
| | Signal Transduction | 3 | 2018 | 4525 | 0.030 |
Why?
| | Erythrocyte Indices | 1 | 2012 | 27 | 0.030 |
Why?
| | Pulmonary Embolism | 1 | 2015 | 184 | 0.030 |
Why?
| | Creatinine | 1 | 2014 | 425 | 0.030 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 390 | 0.030 |
Why?
| | Enzyme Activation | 2 | 1994 | 791 | 0.030 |
Why?
| | Cytomegalovirus Infections | 1 | 1994 | 182 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1203 | 0.030 |
Why?
| | Erythrocyte Transfusion | 1 | 2014 | 186 | 0.030 |
Why?
| | Embolism, Air | 1 | 1992 | 11 | 0.020 |
Why?
| | Biomedical Research | 1 | 2017 | 585 | 0.020 |
Why?
| | Preoperative Care | 2 | 2009 | 318 | 0.020 |
Why?
| | Cell-Derived Microparticles | 1 | 2012 | 58 | 0.020 |
Why?
| | Emotions | 1 | 2016 | 473 | 0.020 |
Why?
| | Chronic Disease | 2 | 2015 | 1591 | 0.020 |
Why?
| | Cardiomegaly | 2 | 2006 | 159 | 0.020 |
Why?
| | Qualitative Research | 1 | 2016 | 934 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 188 | 0.020 |
Why?
| | Mental Health | 1 | 2016 | 559 | 0.020 |
Why?
| | Mortality | 1 | 2012 | 287 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2014 | 351 | 0.020 |
Why?
| | Phenotype | 3 | 2010 | 2815 | 0.020 |
Why?
| | Thromboxane B2 | 1 | 1989 | 27 | 0.020 |
Why?
| | Fellowships and Scholarships | 2 | 1990 | 227 | 0.020 |
Why?
| | Calcimycin | 1 | 1989 | 47 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3350 | 0.020 |
Why?
| | Drug Synergism | 1 | 1990 | 317 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2012 | 544 | 0.020 |
Why?
| | Health Policy | 1 | 2012 | 333 | 0.020 |
Why?
| | Nitric Oxide | 1 | 1994 | 827 | 0.020 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 10 | 0.020 |
Why?
| | Cognition | 1 | 2016 | 983 | 0.020 |
Why?
| | Health Care Costs | 1 | 2012 | 381 | 0.020 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2009 | 22 | 0.020 |
Why?
| | Spironolactone | 1 | 2009 | 28 | 0.020 |
Why?
| | Aromatase | 1 | 2009 | 30 | 0.020 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2009 | 38 | 0.020 |
Why?
| | California | 1 | 2010 | 364 | 0.020 |
Why?
| | Dyspepsia | 1 | 2008 | 9 | 0.020 |
Why?
| | Receptors, Retinoic Acid | 1 | 2009 | 50 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 1989 | 187 | 0.020 |
Why?
| | Pulmonary Veins | 1 | 1989 | 85 | 0.020 |
Why?
| | Cystic Fibrosis | 1 | 1998 | 957 | 0.020 |
Why?
| | Vital Capacity | 1 | 2009 | 257 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1990 | 1036 | 0.020 |
Why?
| | Echocardiography, Transesophageal | 1 | 2009 | 89 | 0.020 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 30 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2009 | 306 | 0.020 |
Why?
| | Vibrio Infections | 1 | 1987 | 2 | 0.020 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 121 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 599 | 0.020 |
Why?
| | American Heart Association | 1 | 2009 | 264 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 2009 | 476 | 0.020 |
Why?
| | Headache | 1 | 2008 | 132 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2009 | 205 | 0.020 |
Why?
| | Endocarditis, Bacterial | 1 | 1987 | 36 | 0.020 |
Why?
| | RNA, Messenger | 2 | 1997 | 2563 | 0.020 |
Why?
| | Protein Biosynthesis | 1 | 1989 | 389 | 0.020 |
Why?
| | Aminorex | 1 | 2006 | 2 | 0.020 |
Why?
| | Heart Rate | 1 | 2010 | 705 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 3 | 2006 | 3116 | 0.020 |
Why?
| | Odds Ratio | 1 | 2009 | 957 | 0.020 |
Why?
| | Alleles | 1 | 2009 | 792 | 0.020 |
Why?
| | Estradiol | 1 | 2009 | 455 | 0.020 |
Why?
| | Hypoventilation | 1 | 1985 | 7 | 0.020 |
Why?
| | Hepatitis C | 1 | 2008 | 226 | 0.020 |
Why?
| | Critical Care | 1 | 1989 | 475 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1997 | 2329 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2005 | 183 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2006 | 298 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2005 | 183 | 0.020 |
Why?
| | Fibroblasts | 1 | 1989 | 839 | 0.020 |
Why?
| | Magnesium | 1 | 1985 | 145 | 0.020 |
Why?
| | Drug Prescriptions | 1 | 2006 | 239 | 0.010 |
Why?
| | Aging | 1 | 1994 | 1624 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1715 | 0.010 |
Why?
| | Pancreatic Elastase | 1 | 2004 | 67 | 0.010 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 1 | 2004 | 48 | 0.010 |
Why?
| | Hypotension | 1 | 1985 | 114 | 0.010 |
Why?
| | Logistic Models | 1 | 2009 | 1839 | 0.010 |
Why?
| | Potassium Channels | 1 | 2004 | 121 | 0.010 |
Why?
| | DNA | 1 | 1990 | 1352 | 0.010 |
Why?
| | Research Design | 1 | 2009 | 930 | 0.010 |
Why?
| | Tablets | 1 | 2003 | 36 | 0.010 |
Why?
| | Arginine | 1 | 2004 | 238 | 0.010 |
Why?
| | Sex Factors | 1 | 2008 | 1721 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2010 | 976 | 0.010 |
Why?
| | Angiotensin II | 1 | 2003 | 91 | 0.010 |
Why?
| | Rats | 2 | 2004 | 4973 | 0.010 |
Why?
| | Sepsis | 1 | 1987 | 508 | 0.010 |
Why?
| | Liver Transplantation | 1 | 2009 | 774 | 0.010 |
Why?
| | Practice Patterns, Physicians' | 1 | 2010 | 1177 | 0.010 |
Why?
| | Heart Ventricles | 1 | 2006 | 714 | 0.010 |
Why?
| | Ovarian Neoplasms | 1 | 2005 | 386 | 0.010 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 372 | 0.010 |
Why?
| | Colorimetry | 1 | 2000 | 14 | 0.010 |
Why?
| | Spinal Osteophytosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Spinal Cord Compression | 1 | 1999 | 17 | 0.010 |
Why?
| | Spinal Stenosis | 1 | 1999 | 24 | 0.010 |
Why?
| | Heart Atria | 1 | 2000 | 111 | 0.010 |
Why?
| | Veins | 1 | 1999 | 57 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 1999 | 292 | 0.010 |
Why?
| | Calcium-Transporting ATPases | 1 | 1997 | 35 | 0.010 |
Why?
| | Atrial Natriuretic Factor | 1 | 1997 | 57 | 0.010 |
Why?
| | Heart-Lung Transplantation | 1 | 1997 | 10 | 0.010 |
Why?
| | Arteries | 1 | 1999 | 249 | 0.010 |
Why?
| | Liver Cirrhosis | 1 | 1999 | 235 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 286 | 0.010 |
Why?
| | Models, Biological | 1 | 2004 | 1636 | 0.010 |
Why?
| | Spinal Cord | 1 | 1999 | 348 | 0.010 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 133 | 0.010 |
Why?
| | Diverticulitis, Colonic | 1 | 1996 | 7 | 0.010 |
Why?
| | Systole | 1 | 1997 | 171 | 0.010 |
Why?
| | Blotting, Western | 1 | 1999 | 1149 | 0.010 |
Why?
| | von Willebrand Factor | 1 | 1996 | 56 | 0.010 |
Why?
| | Proteins | 2 | 1992 | 915 | 0.010 |
Why?
| | Ventricular Function, Left | 1 | 1999 | 469 | 0.010 |
Why?
| | Respiration | 1 | 1996 | 182 | 0.010 |
Why?
| | Physical Fitness | 1 | 1997 | 179 | 0.010 |
Why?
| | Cilazapril | 1 | 1995 | 2 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 1995 | 25 | 0.010 |
Why?
| | Tissue Donors | 1 | 1997 | 326 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 1999 | 698 | 0.010 |
Why?
| | Thymidine | 1 | 1994 | 58 | 0.010 |
Why?
| | Ganciclovir | 1 | 1994 | 49 | 0.010 |
Why?
| | Subcellular Fractions | 1 | 1994 | 78 | 0.010 |
Why?
| | Lung Diseases, Obstructive | 1 | 1994 | 40 | 0.010 |
Why?
| | Opportunistic Infections | 1 | 1994 | 43 | 0.010 |
Why?
| | Liver | 1 | 2002 | 1681 | 0.010 |
Why?
| | Blood | 1 | 1994 | 97 | 0.010 |
Why?
| | Acyclovir | 1 | 1994 | 100 | 0.010 |
Why?
| | Factor VIII | 1 | 1994 | 54 | 0.010 |
Why?
| | Vimentin | 1 | 1994 | 58 | 0.010 |
Why?
| | Viremia | 1 | 1994 | 122 | 0.010 |
Why?
| | Immunoglobulins, Intravenous | 1 | 1994 | 121 | 0.010 |
Why?
| | Gene Expression | 1 | 1998 | 1423 | 0.010 |
Why?
| | Immunocompromised Host | 1 | 1994 | 196 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 1994 | 641 | 0.010 |
Why?
| | Sputum | 1 | 1994 | 285 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 1994 | 281 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1991 | 193 | 0.010 |
Why?
| | Lymph | 1 | 1992 | 40 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 1994 | 522 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1994 | 1084 | 0.010 |
Why?
| | Extracellular Matrix Proteins | 1 | 1991 | 126 | 0.010 |
Why?
| | Financing, Government | 1 | 1990 | 40 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 1999 | 2341 | 0.010 |
Why?
| | National Institutes of Health (U.S.) | 1 | 1990 | 106 | 0.010 |
Why?
| | Career Mobility | 1 | 1990 | 63 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1995 | 2212 | 0.010 |
Why?
| | Research Support as Topic | 1 | 1990 | 108 | 0.010 |
Why?
| | Pneumonia, Viral | 1 | 1994 | 342 | 0.010 |
Why?
| | Sheep | 1 | 1992 | 764 | 0.010 |
Why?
| | Vibrio | 1 | 1987 | 3 | 0.000 |
Why?
| | Hepatitis, Alcoholic | 1 | 1987 | 13 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1997 | 2150 | 0.000 |
Why?
| | Protein Binding | 1 | 1992 | 1898 | 0.000 |
Why?
| | Citrates | 1 | 1985 | 43 | 0.000 |
Why?
| | RNA | 1 | 1991 | 810 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1995 | 3545 | 0.000 |
Why?
| | Anti-Bacterial Agents | 1 | 1994 | 1477 | 0.000 |
Why?
| | Kidney Function Tests | 1 | 1985 | 141 | 0.000 |
Why?
| | HIV Infections | 1 | 1999 | 2470 | 0.000 |
Why?
| | Infant | 1 | 1994 | 7945 | 0.000 |
Why?
|
|
Badesch's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|